Yahoo Finance

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Yahoo Finance

Global Carcinoid Syndrome Market Poised for Growth Through 2035 as Treatment Innovation and Diagnosis Rates Advance

Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Carcinoid Syndrome Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ResearchAndMarkets.com's ...
Nasdaq

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a ...
Medical News Today

Xermelo dosage

Xermelo’s (telotristat ethyl) dosage for carcinoid syndrome diarrhea is typically 250 milligrams (mg) three times per day. Your dosing may vary based on your symptoms and other medications you’re ...
Digital Journal

Carcinoid Syndrome Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

DelveInsight added a report on “Carcinoid Syndrome Market“. It covers an overview, its causes, signs and symptoms, and therapies. Major players are involved in developing therapies for Carcinoid ...
Business Insider

Crinetics Pharmaceuticals: A Leading Prospect in Acromegaly and Carcinoid Syndrome Treatments – An Optimistic Outlook based on PATHFNDR Trials and Potential Market Upside

Brian Skorney, an analyst from Robert W. Baird, maintained the Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report). The associated price target is $45.00. Brian Skorney has given his Buy ...
ascopubs.org

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III ...
Becker's Hospital Review

Lexicon earns FDA approval for carcinoid syndrome diarrhea drug

Carcinoid syndrome is a rare condition that occurs in patients with gastrointestinal tumors. These patients secrete an excessive amount of serotonin, which can lead to symptoms like frequent diarrhea, ...
ascopubs.org

Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.

Antiproliferative activity of octreotide LAR in advanced neuroendocrine tumors. Octreotide LAR (OCT-L) among elderly patients with stage IV neuroendocrine tumors (NETs): A survival analysis of ...
Benzinga.com

Amryt Shares Shoot Higher As FDA Grants Orphan Drug Status To Carcinoid Tumor Candidate

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s AMYT lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most common ...
Medscape

Persistent Erythema, Telangiectases, and Facial Flushing After Carcinoid Tumor Excision

A 26-year-old woman with an uneventful family medical history presented for evaluation and treatment of a facial dermatosis of 6 years duration. Examination revealed an intense erythema symmetrically ...